Sharon Townson
Chief Tech/Sci/R&D Officer chez MONTE ROSA THERAPEUTICS, INC.
Profil
Sharon Townson is currently the Chief Technology Officer at Monte Rosa Therapeutics, Inc. She previously worked as the Scientific Director-Physical Biochemistry at Warp Drive Bio, Inc. from 2016 to 2018 and as the Executive Director & Head-Platform Biology at Kymera Therapeutics, Inc. from 2019 to 2020.
Dr. Townson obtained her undergraduate degree from the University of Salford and her doctorate degree from the University of Manchester Institute of Science & Technology.
Postes actifs de Sharon Townson
| Sociétés | Poste | Début |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2021 |
Anciens postes connus de Sharon Townson
| Sociétés | Poste | Fin |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Director/Board Member | 01/06/2020 |
Warp Drive Bio, Inc.
 Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Warp Drive Bio, Inc. focused on proprietary genomic technology to discover drugs of natural origin. The firm deployed proprietary platforms Genome Mining and Small Molecule Assisted Receptor Targeting (SMART) to discover and develop novel molecules addressing new pharmacologic mechanisms. The company was founded by Gregory L. Verdine, George McDonald Church, and James A. Wells in 2012 and was headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/12/2018 |
Formation de Sharon Townson
| University of Salford | Undergraduate Degree |
| University of Manchester Institute of Science & Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| KYMERA THERAPEUTICS, INC. | Health Technology |
| MONTE ROSA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Warp Drive Bio, Inc.
Warp Drive Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Warp Drive Bio, Inc. focused on proprietary genomic technology to discover drugs of natural origin. The firm deployed proprietary platforms Genome Mining and Small Molecule Assisted Receptor Targeting (SMART) to discover and develop novel molecules addressing new pharmacologic mechanisms. The company was founded by Gregory L. Verdine, George McDonald Church, and James A. Wells in 2012 and was headquartered in Cambridge, MA. | Commercial Services |
